SCHOLAR ROCK HOLDING CORPORATION Increase (Decrease) in Deferred Charges
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Increase (Decrease) in Deferred Charges of -$191.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2020-03-12
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in deferred charges for the quarter ending 2018-12-31 was -$1.00K.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in deferred charges for the quarter ending 2018-09-30 was -$205.00K.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in deferred charges for the quarter ending 2018-06-30 was -$17.00K.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in deferred charges for the quarter ending 2018-03-31 was $32.00K.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in deferred charges for fiscal 2018 was -$191.00K, a 191.39% decline from fiscal 2017.
- SCHOLAR ROCK HOLDING CORPORATION increase (decrease) in deferred charges for fiscal 2017 was $209.00K.
| Period end | Increase (Decrease) in Deferred Charges 3 month | Increase (Decrease) in Deferred Charges 6 month | Increase (Decrease) in Deferred Charges 9 month | Increase (Decrease) in Deferred Charges 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$206.00K derived: sum of 2 quarters · filed 2020-03-12 | -$223.00K derived: sum of 3 quarters · filed 2020-03-12 | -$191.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | -$205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$222.00K derived: sum of 2 quarters · filed 2019-11-12 | -$190.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $15.00K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $32.00K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $209.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |